Cure
Overview
Philadelphia is where modern cell and gene therapy was born, and the field is still concentrated there. Here are seven companies driving the region's life sciences scene, from gene therapy to obesity drugs.
Philadelphia has one of the oldest and densest life sciences economies in the country, and it still gets talked about less than Boston or San Diego. Alex Dugom, General Partner at InoSwift Capital Fund, sees that gap as a matter of attention, not substance. His fund invests at the Series A stage in longevity and frontier deep tech, which gives him a read across emerging biotech markets, and Philadelphia keeps coming up as underrated.
"Philly is one of the most established life sciences ecosystems in the country, but I believe it gets overlooked," he said. Outside of Indianapolis, Dugom argues, it is difficult to find another market that combines Philadelphia’s pharma density, institutional expertise, and transaction scale.
A core strength of Philadelphia as a life sciences hub is the depth of expertise across the region. Dugom pointed out that between Philadelphia and New Jersey, there’s a historically dense network of pharma and life sciences companies, world-class medical and research institutions, and access to the broader Northeast talent pool. “There’s a level of operational and intellectual maturity there that you notice pretty quickly,” he added.
That depth is also reflected in the region’s scientific talent. “The scientific talent is also unusually deep, partly because of the sheer size of the industry and partly because the academic community has developed very specialized programs in areas like drug development and pharmaceuticals,” Dugom said.
Looking ahead, Dugom sees entrepreneurship as the next major opportunity for biotech in Philadelphia. The region already has the talent and infrastructure to support new companies; the challenge is connecting those pieces more effectively. “The talent and infrastructure are already there. What’s missing is more of the entrepreneurial and technical development layer connecting the two,” he said.
The seven companies highlighted below reflect the depth and diversity of Philadelphia’s life sciences sector, spanning established biotech players, emerging companies, and organizations advancing drug development and other areas of innovation.
Spark Therapeutics
Sector: Gene therapy, specifically inherited retinal disease, hemophilia, neurodegenerative, and liver-targeted disorders
HQ: 3737 Market Street, Suite 1300, Philadelphia, PA 19104
Year Founded: 2013
Key Leaders: Sylke Poehling, PhD, took over as CEO in August 2024. She also remains SVP and Global Head of Therapeutic Modalities at Roche.
Number of Employees: 264 as of March 2026 (unit size cited when Ron Philip took over as CEO in 2022; Spark now operates as a wholly owned Roche division rather than a standalone reporting company)
Stage / Funding Round: Spark is a wholly owned operating subsidiary of the Roche Group. The transaction was valued at approximately $4.8 billion in total equity value.
Financial Snapshot: No standalone public financials since the Roche acquisition; Spark helped anchor a $575 million gene therapy manufacturing center on Drexel University's campus in Philadelphia.
Key Products / Pipeline: Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for a genetic disease, treating an inherited form of blindness. Their pipeline also includes SPK-3006 for Pompe disease and clinical hemophilia programs (such as fidanacogene elaparvovec for Hemophilia B, which was developed with Pfizer and approved in 2024)
Recent Highlights: Spark named Sylke Poehling as its new CEO in September 2024, succeeding Ron Philip. The company continues to anchor Philadelphia's "Cellicon Valley" cell-and-gene-therapy cluster, with its Drexel-based Gene Therapy Innovation Center planned as a Roche center of excellence for gene-therapy manufacturing, while operating under Roche's global R&D structure.
Century Therapeutics
Sector: Induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer and autoimmune disease, including type 1 diabetes
HQ: 25 N. 38th Street, 11th Floor, Philadelphia, PA 19104
Year Founded: 2018
Key Leaders: Brent Pfeiffenberger, Pharm.D., serves as the Chief Executive Officer, taking the helm in late 2023.
Number of Employees: 77 as of March 2026
Stage / Funding Round: Publicly traded (Nasdaq: IPSC)
Financial Snapshot: Market cap roughly $371 million with $181 million in shares as of mid-2026. Cash, cash equivalents, and marketable securities were $217 million as of March 31, 2026, with runway extended into 1Q 2029 following an oversubscribed $135 million private placement in January 2026.
Notable Investors: Venrock Healthcare Capital Partners, RA Capital Management, RTW Investments, TCG Crossover, Deep Track Capital. Century Therapeutics’ established cell therapy platform co-development collaboration remains with Bristol Myers Squibb.
Key Products / Pipeline: CNTY-813, an Allo-Evasion-engineered iPSC-derived beta islet replacement therapy for type 1 diabetes, tracking toward an IND submission in Q4 2026; CNTY-308, a CD19-targeted CAR-iT cell therapy expected to enter the clinic in 2026; CNTY-101, an earlier CD19-targeted CAR-iNK program
Recent Highlights: Century closed an oversubscribed $135 million private placement in January 2026, extending its cash runway to early 2029. The company reported durable preclinical in vivo glucose control data for CNTY-813 and is presenting at the ADA, EASD, and Breakthrough T1D congresses through the back half of 2026 as it pushes toward an IND filing.
Cabaletta Bio
Sector: Engineered CAR T-cell therapies for B cell-mediated autoimmune disease
HQ: 2929 Arch Street, Suite 600, Philadelphia, PA 19104
Year Founded: 2017
Key Leaders: Steven Nichtberger, M.D., serves as co-founder, President, and Chief Executive Officer.
Number of Employees: 160 as of March 2026
Stage / Funding Round: Late-stage clinical, publicly traded (Nasdaq: CABA)
Financial Snapshot: The company’s market cap was approximately $552 million as of September 2026.
Key Products / Pipeline: Resecabtagene autoleucel (rese-cel), a fully human, 4-1BB-containing CD19-CAR T-cell therapy being evaluated across the RESET clinical program in myositis, lupus, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris
Recent Highlights: At EULAR 2026, 80% of evaluable adult dermatomyositis and antisynthetase-syndrome patients (8 of 10) met the registrational primary endpoint, with responses holding through 1.5 years of follow-up. Cabaletta added ElevateBio as a second manufacturing partner alongside Lonza, plans to begin a registrational systemic sclerosis-ILD study in Q4 2026, and is targeting its first BLA submission for myositis in the second half of 2027.
Alveus Therapeutics
Sector: Obesity and metabolic disease — incretin and amylin biology
HQ: Two Logan Square, Suite 1930, Philadelphia, PA 19103; also has an office in Copenhagen, Denmark.
Year Founded: 2023
Key Leaders: Raj Kannan, CEO; Jacob Jeppesen, PhD, Chief Scientific Officer; John Stubenrauch, PhD, Chief Technology Officer
Number of Employees: 34
Stage / Funding Round: It is a privately held, clinical-stage company backed by a major Series A investment group.
Financial Snapshot: $197 million total Series A financing, following an initial $159.8 million close in January 2026 and a second, oversubscribed close in February 2026
Notable Investors: New Rhein Healthcare Investors, Andera Partners, and Omega Funds (co-lead syndicate), with Sanofi Capital, Kurma Partners, Avego BioScience Capital, Jeito Capital, and Novo Holdings also participating
Key Products / Pipeline: Alveus Therapeutics is advancing ALV-100, a bifunctional GIP receptor antagonist and GLP-1 receptor agonist fusion protein, is in Phase 2 for chronic weight management. The company is also progressing ALV-200, a selective AMYR3 amylin receptor peptide agonist, into IND-enabling studies alongside early-stage oral small-molecule amylin programs. The pipeline also includes ALV-300, an oral small molecule targeting dual amylin-calcitonin receptor pharmacology.
Recent Highlights: Alveus launched publicly with a $159.8 million Series A, then expanded its investor syndicate to include Jeito Capital and Novo Holdings at its February 2026 second close, bringing total Series A proceeds to $197 million to fund ALV-100 through Phase 2 and advance its amylin pipeline toward the clinic.
Interius BioTherapeutics
Sector: In vivo CAR T-cell therapy for B-cell malignancies
HQ: 3401 Grays Ferry Avenue, Building 200, Suite 300, Philadelphia, PA 19146
Year Founded: 2019
Key Leaders: Interius’s operations and its team have been integrated into Kite Pharma's research division; Cindy Perettie is the President of Kite Pharma.
Number of Employees: 19
Stage / Funding Round: Acquired outright by Kite Pharma, a Gilead Sciences company, in August 2025 for $350 million in cash; no longer an independent company
Financial Snapshot: $350 million all-cash acquisition price; prior private backers included Fairmount Funds Management and Canton Strategic Holdings
Notable Investors: Fairmount Funds Management, Canton Strategic Holdings; acquirer Kite/Gilead Sciences
Key Products / Pipeline: INT2104, an in vivo CAR-T candidate for B-cell malignancies that uses a proprietary lentiviral vector to engineer immune cells directly inside the patient's spleen, bone marrow, and lymph nodes. This eliminates the harvesting, manufacturing, and chemotherapy preconditioning steps required by conventional CAR-T
Recent Highlights: After dosing its first patient in Australia in October 2024 and reporting potent, cytokine-release-free B-cell depletion in preclinical models, Interius was acquired by Kite in a deal announced in August 2025. It's Kite's second Philadelphia-area acquisition after 2023's Tmunity Therapeutics purchase, and Kite says it will build a Philadelphia "center of excellence" around the Interius team to keep developing in vivo cell therapies locally.
Vittoria Biotherapeutics
Sector: Gene-edited CAR T-cell therapies for oncology and autoimmune disease
HQ: 3675 Market Street, Suite 200, Philadelphia, PA 19104
Year Founded: 2021
Key Leaders: Nicholas A. Siciliano, PhD, Co-Founder and CEO; Keith Westby, MBA, COO; Rosemary Mazanet, MD, PhD, Chief Medical Officer
Number of Employees: ~12
Stage / Funding Round: The company has raised $25 million in total private financing. However, the initial round was $15 million in November 2023, and the remaining $10 million extension closed a year later, in November 2024, led by Valley Forge Investment Corporation.
Financial Snapshot: Total funding to date of approximately $25 million; no public financials
Notable Investors: Backers include Agent Capital, BioAdvance, and Ben Franklin Technology Partners.
Key Products / Pipeline: Their lead candidate is VIPER-101, an autologous, CD5-knockout dual-population CAR-T therapy for relapsed/refractory CD5-positive T-cell lymphoma. It leverages the proprietary Senza5 platform licensed from the University of Pennsylvania.
Recent Highlights: Vittoria's Phase 1 trial of VIPER-101 is enrolling at the University of Pennsylvania and has expanded to additional sites. The company presented preclinical data on its Senza5 platform at ASH in December 2024, shared trial-in-progress data at ASCO 2026, and won the Penn Center for Innovation's Startup of the Year award in 2025.
FORE Biotherapeutics
Sector: Precision oncology — targeted therapies for BRAF-altered cancers
HQ: 3675 Market Street, Suite 200, Philadelphia, PA 19104
Year Founded: 2011 (as NovellusDx); renamed FORE Biotherapeutics and moved its global HQ to Philadelphia in 2021
Key Leaders: William R. Hinshaw, President and Chief Executive Officer; Michael Byrnes, Chief Financial Officer
Number of Employees: ~49
Stage / Funding Round: The company successfully closed an upsized $67.4 million Series D-2 extension. This brought the total raised specifically for the Series D-2 round to $110 million.
Financial Snapshot: Has raised approximately $219 million in venture funding to date. This includes its foundational early rounds as NovellusDx, a $75 million Series D/D-1 block in 2023, and the recently fully allocated $110 million Series D-2 financing structure, which consists of a $38 million initial close in 2025 and a $67.4 million extension in July 2026.
Notable Investors: The company is backed by a robust international syndicate co-led by SR One, Medicxi, and SymBiosis. Other notable institutional investors include OrbiMed Advisors, Wellington Management, and recent extension backers like LG Technology Ventures and TaiAx.
Key Products / Pipeline: Their clinical focus rests on plixorafenib (FORE8394), a unique "dimer breaker" and "paradox breaker" BRAF inhibitor running on the global Phase 2 FORTE Master Protocol.
Recent Highlights: The FDA granted plixorafenib Breakthrough Therapy Designation in April 2026 for BRAF V600E-mutated high-grade glioma, which Fore says is the first BTD granted to a targeted therapy for high-grade glioma. The company reached target enrollment in its BRAF V600E primary CNS tumor basket and expects topline registrational data by the end of 2026, with a potential FDA submission under the Accelerated Approval pathway if the primary analysis is positive.
